Missouri Patent of the Month – February 2025
Humanwell Pharmaceutical US, Inc. has developed a breakthrough in kappa opioid receptor (KOR) peptide ligands with the invention of a novel tetrapeptide compound. This innovation presents a promising new class of KOR-selective agonists designed to address pain and pruritus while minimizing the adverse effects typically associated with traditional opioid medications.
The invention introduces a kappa opioid receptor peptide ligand of Formula (I), where the carefully selected D-amino acid sequence enhances receptor selectivity and potency. Unlike previous KOR agonists that failed due to side effects such as dysphoria and sedation, this novel compound aims to provide effective therapeutic benefits without compromising patient comfort and safety.
KORs are critical in modulating pain perception, mood, and immune responses. While earlier attempts at developing KOR-targeting analgesics encountered setbacks, Humanwell’s new peptide-based ligand leverages advances in molecular design to overcome these challenges. The compound’s structure not only ensures high affinity for KORs but also improves pharmacokinetic properties, making it a strong candidate for clinical application.
Beyond pain management, the invention holds potential for treating conditions such as chronic itching (pruritus), irritable bowel syndrome, and certain neurological disorders. By focusing on a selective and refined molecular approach, Humanwell aims to provide an alternative to conventional opioids, addressing the growing need for safer analgesics amid the opioid crisis.
This invention marks a significant step forward in peptide-based pharmacotherapy. As research progresses, this KOR peptide ligand may redefine treatment strategies for pain and other KOR-related conditions, offering patients relief with fewer risks and improved efficacy.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
